Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

HemaGenetics Technologies Announces Share Distribution Record Date with Subsidiaries under Plan of Arrangement
BiotechnologyCompany Update

HemaGenetics Technologies Announces Share Distribution Record Date with Subsidiaries under Plan of Arrangement

June 5, 2020 3:50 PM

VANCOUVER, BC / ACCESSWIRE / June 5, 2020 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that it has set the share distribution record date for the Arrangement with 1207326 B.C. LTD., 1207331 B.C. LTD., 1207334 B.C. LTD., 1207335 B.C. LTD., 1207378 B.C. LTD., 1207380 B.C. LTD., 1207382 B.C. LTD., 1208614 B.C. LTD., 1209629 B.C. LTD., 1209631 B.C. LTD., 1210352 B.C. LTD., and 1211319 B.C. LTD. (collectively, the...

Read more
Tetra Bio-Pharma's Pleased to Announce Advancement of QIXLEEF(TM) and CAUMZ(TM) Clinical Trials Ahead of Annual General Meeting
BiotechnologyCompany Update

Tetra Bio-Pharma's Pleased to Announce Advancement of QIXLEEF(TM) and CAUMZ(TM) Clinical Trials Ahead of Annual General Meeting

June 5, 2020 8:00 AM

Resumption of its PLENITUDE© clinical trial to bring QIXLEEF™ to market ReBorn© clinical trial to resume to bring CAUMZ™ to the market as an alternative to opioids for breakthrough pain QIXLEEF™ metabolite mapping ongoing OTTAWA, ON / ACCESSWIRE / June 5, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery, today announced that the...

Read more
DECN CEO Interviewed On Vancouver's #1 News/Talk Radio Station, Discusses GenViro! Covid-19 :15 Swift Test Kit, Additional Interviews Anticipated
BiotechnologyCompany Update

DECN CEO Interviewed On Vancouver's #1 News/Talk Radio Station, Discusses GenViro! Covid-19 :15 Swift Test Kit, Additional Interviews Anticipated

June 4, 2020 9:10 AM

LOS ANGELES, CA / ACCESSWIRE / June 4, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc. today made available CEO Keith Berman's recent interview on radio station CKNW, Vancouver's #1 rated News/Talk Radio station in the adult 35-64 sector. Berman appeared LIVE with talk show host John Daly on his "Daly Back on the Beat," Show and discussed the Decision Diagnostics GenViro! Covid-19 :15 Swift...

Read more
Tetra Bio-Pharma and Storz & Bickel Enter into Commercial Sales Agreement for the Mighty Medic Vaporizer
BiotechnologyPartnerships

Tetra Bio-Pharma and Storz & Bickel Enter into Commercial Sales Agreement for the Mighty Medic Vaporizer

June 4, 2020 8:00 AM

OTTAWA, ON / ACCESSWIRE / June 4, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development and Storz & Bickel, a subsidiary of Canopy Growth Corporation, (TSX:WEED)(NYSE:CGC), a world-leading diversified cannabis, hemp and cannabis device company, are pleased to announce that they have finalized a definitive commercial sales...

Read more
Wuhan General Group Strengthens Team with New Appointments
BiotechnologyCompany Update

Wuhan General Group Strengthens Team with New Appointments

June 3, 2020 8:30 AM

MONTREAL, QC / ACCESSWIRE / June 3, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the newly appointed members of the Company. Mr. Johann McLoughlin hails from the creative hub of Cape Town, South Africa. He joins Wuhan effective immediately as Director of Product Development and Visual...

Read more
Tetra Bio-Pharma and Altus Formulation Form New Company
BiotechnologyPartnerships

Tetra Bio-Pharma and Altus Formulation Form New Company "TALLC" to Exploit TA-A001

June 3, 2020 8:00 AM

OTTAWA, ON / ACCESSWIRE / June 3, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF) and Altus Formulation Inc. ("Altus") today announced the launch of TALLC Corporation Inc. ("TALLC") a new Quebec company focussed on the development of TA-A001 a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. With initial funding provided from Altus and Tetra, and under a new...

Read more
Nascent Biotech's CEO Provides Corporate Updates on Phase I Brain Cancer Trial and COVID-19 Development Initiative on SNN Network
BiotechnologyCompany Update

Nascent Biotech's CEO Provides Corporate Updates on Phase I Brain Cancer Trial and COVID-19 Development Initiative on SNN Network

June 3, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / June 3, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) (the "Company" or "Nascent") is pleased to provide a corporate update and summary with a recent interview the Company's CEO, Sean Carrick, presented on SNN Network. The complete interview may be seen on the SNN Network at https://www.youtube.com/watch?v=bq-iWU9Ss_E&t=93s. Mr. Carrick indicates," As the Company moves forward with execution of its active 2020 agenda,...

Read more
Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells
BiotechnologyCompany Update

Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

June 2, 2020 1:10 PM

GOLDEN, CO / ACCESSWIRE / June 2, 2020 / Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. ("GIOSTAR") a leading stem cell research institute based in San Diego, California to jointly partner together for a COVID-19 Investigational New Drug ("IND") to the FDA using Vitro Biopharma's umbilical cord mesenchymal stem cell...

Read more
Citizen Stash Enters the Province of Ontario
BiotechnologyCompany Update

Citizen Stash Enters the Province of Ontario

June 2, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / June 2, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce the launch of its premium brand, Citizen Stash, into Ontario where it will be available in stores and online (ocs.ca) in the coming weeks. The Company's wholly-owned subsidiary, Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of top shelf cannabis, has...

Read more
Aqualung Therapeutics Corporation Receives A $2.3 Million National Institute Of Health (NIH) Fast-Track Award To Develop A Novel Therapeutic Antibody For Patients With Radiation-Induced Lung Injury
BiotechnologyCompany Update

Aqualung Therapeutics Corporation Receives A $2.3 Million National Institute Of Health (NIH) Fast-Track Award To Develop A Novel Therapeutic Antibody For Patients With Radiation-Induced Lung Injury

June 2, 2020 8:00 AM

TUCSON, AZ / ACCESSWIRE / June 2, 2020 / Aqualung Therapeutics, an early-stage biotech company developing immune-focused therapeutic antibodies for patients suffering from acute and chronic disorders characterized by systemic inflammation, has been awarded a three year NIH FAST-TRACK AWARD (R42 HL152888-01) which will support mid- and late-stage development of a therapeutic to treat patients who undergo radiotherapy for treatment of lung &...

Read more
Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA
BiotechnologyRegulatory

Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA

June 2, 2020 8:00 AM

HCC011 is an orphan drug designated drug-device combination product for the treatment of hepatocellular carcinoma (HCC) OTTAWA, ON / ACCESSWIRE / June 2, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has completed a Type B meeting with the United States Food and Drug Administration (FDA) for its drug-device...

Read more
Hancock Jaffe Announces Registered Direct Offering Priced At Market
BiotechnologyCompany Update

Hancock Jaffe Announces Registered Direct Offering Priced At Market

June 1, 2020 2:45 PM

IRVINE, CA / ACCESSWIRE / June 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $1.333 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent...

Read more
Hancock Jaffe Announces Intention to Merge with Catheter Precision
BiotechnologyCompany Update

Hancock Jaffe Announces Intention to Merge with Catheter Precision

June 1, 2020 8:30 AM

Companies Sign Non-Binding Letter of Intent to Merge IRVINE, CA / ACCESSWIRE / June 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has signed a non-binding letter of intent to merge with Catheter Precision, Inc., a private medical device company focused on cardiovascular diseases, including heart arrythmias. Catheter...

Read more
Experion Reports AGM Results
BiotechnologyCompany UpdateShareholder Meeting

Experion Reports AGM Results

May 29, 2020 8:00 PM

VANCOUVER, BC / ACCESSWIRE / May 29 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce the results of its annual general and special meeting of the shareholders held on May 27, 2020 (the "Meeting") The Company put forward the following resolutions to be voted on by shareholders at the Meeting, all of which were approved: (i) Fixing the number of directors of the...

Read more
Pieris Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
BiotechnologyConferences

Pieris Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

May 28, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / May 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today that management will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 PM EDT. A webcast of the company's presentation...

Read more
Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy
BiotechnologyCompany Update

Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy

May 28, 2020 3:00 AM

Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics' virosomes were tested by Stallergenes Greer in a therapeutic model of birch pollen allergy. The results showed that a treatment with COP-virosomes was able to cure allergic asthma in birch pollen sensitized mice. The COP-virosomes were significantly superior to the COP or the virosome alone, confirming...

Read more
Pacylex Presents as Medical and Investment Conferences Go Virtual
BiotechnologyCompany Update

Pacylex Presents as Medical and Investment Conferences Go Virtual

May 27, 2020 9:00 AM

Pacylex will present three posters at two upcoming medical conferences, and participate in the Annual BIO Meeting EDMONTON, ALBERTA, CANADA / ACCESSWIRE / May 27, 2020 / PACYLEX PHARMACEUTICALS, INC. a pre-IND-stage pharmaceutical company targeting cancers with a new first-in-class therapeutic, announced today that its chief executive officer, Michael Weickert, will participate in the BIO 2020 conference being held virtually June 8-12,...

Read more
AQUALUNG THERAPEUTICS CORP. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS and the Critically Ill
BiotechnologyCompany Update

AQUALUNG THERAPEUTICS CORP. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS and the Critically Ill

May 27, 2020 9:00 AM

New Hope for Treating Major Cause of COVID-19 Deaths Even before the COVID-19 Pandemic, each year 500,000 patients in the US, 2 million patients globally, develop ARDS due to bacterial and viral causes of pneumonia, trauma and other infections TUCSON, AZ / ACCESSWIRE / May 27, 2020 / In June 2019, Aqualung Therapeutics received a three year $1.7M dollar NIH Fastrack Award, for development of a novel immune-based anti-inflammatory...

Read more
Tetra Bio-Pharma Announces Foreign Patent and Reinforces its Ophthalmic IP Portfolio with a New Australian Patent
BiotechnologyCompany Update

Tetra Bio-Pharma Announces Foreign Patent and Reinforces its Ophthalmic IP Portfolio with a New Australian Patent

May 26, 2020 8:00 AM

OTTAWA, ON / ACCESSWIRE / May 26, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, announces granting of a new patent from the Australian Patent Office for patent application number 2016268872. This represents the company's first foreign patent and a Notice of Acceptance appeared in the Australian Official Journal of...

Read more
One of the Richest Entrepreneurs Onur Agaoglu is Investing 5 Million USD in New Business Ideas
BiotechnologyCompany Update

One of the Richest Entrepreneurs Onur Agaoglu is Investing 5 Million USD in New Business Ideas

May 25, 2020 11:50 AM

ISTANBUL, TURKEY / ACCESSWIRE / May 25, 2020 / Onur Agaoglu, Member of the Board at Agaoglu Group and Founder of Agaoglu Concept, announced that he will establish a venture capital company with an investment of 5 million USD in new business ideas especially in blockchain technologies and artificial intelligence. Onur Agaoglu, Member of the Board at Agaoglu Group and Founder of the Agaoglu Concept, also the nephew of Forbes billionaire...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?